GlassScriptPhysician profile
Michelle Balderas
NPI 1164076717
$3,495.96
in general payments reported to CMS, 2019-2025
34 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,453 · 2022: $813 · 2023: $450 · 2024: $289 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,003.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $332.34 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $268.20 | 2022-2025 | Rybelsus, Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $237.36 | 2021-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.00 | 2021-2024 | Xifaxan |
| Amarin Pharma, INC. | $142.49 | 2021-2022 | |
| Lilly USA, LLC | $139.82 | 2021-2025 | Mounjaro, Zepbound |
| Fresenius Kabi USA, LLC | $125.00 | 2025 | Smoflipid |
| Nabriva Therapeutics, Plc | $110.71 | 2022 | |
| Paratek Pharmaceuticals, INC. | $94.66 | 2021-2024 | Nuzyra |
| Currax Pharmaceuticals LLC | $92.72 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.49 | 2022 | |
| Genentech USA, INC. | $55.69 | 2021-2022 | |
| Amgen INC. | $54.91 | 2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $51.38 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $46.91 | 2022-2023 | Quviviq |
| Pfizer INC. | $46.39 | 2024-2025 | |
| Exact Sciences Corporation | $44.40 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $44.23 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.56 | 2023-2024 | Jardiance |
| Intuitive Surgical, INC. | $37.47 | 2024 | |
| Becton, Dickinson and Company | $33.20 | 2021-2023 | Bd Onclarity |
| Janssen Pharmaceuticals, INC | $30.12 | 2021 | |
| Optinose US, INC. | $28.09 | 2025 | |
| Exeltis, USA INC. | $24.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.97 | 2023 | Trintellix |
| Vbi Vaccine (Delaware) INC. | $22.36 | 2022 | |
| Dynavax Technologies Corporation | $21.60 | 2023 | Heplisav-B |
| Eisai INC. | $20.24 | 2021 | |
| Shield Therapeutics INC | $19.48 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.56 | 2025 | Recorlev |
| Phadia US INC. | $14.59 | 2023 | Immunocap |
| Ascensia Diabetes Care US INC. | $14.08 | 2021 | |
| Dexcom, INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Balderas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.